EGFR and neoplasm: Moreover, both in vitro and in vivo trials revealed that inhibition of FGD5-AS1 can release the inhibition of tumor suppressor miR-330-3p, thereby down-regulating the expression of oncogene HK2 and the level of glycolysis and overcoming EGFR-induced 5-fu resistance in rectal cancer cells.